S&P 500   3,925.43 (+1.14%)
DOW   31,961.86 (+1.35%)
QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
S&P 500   3,925.43 (+1.14%)
DOW   31,961.86 (+1.35%)
QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
S&P 500   3,925.43 (+1.14%)
DOW   31,961.86 (+1.35%)
QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
S&P 500   3,925.43 (+1.14%)
DOW   31,961.86 (+1.35%)
QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
Log in
NASDAQ:SYBX

Synlogic Stock Forecast, Price & News

$4.03
-0.01 (-0.25 %)
(As of 02/24/2021 04:30 PM ET)
Add
Compare
Today's Range
$3.94
Now: $4.03
$4.11
50-Day Range
$2.24
MA: $3.87
$5.05
52-Week Range
$1.35
Now: $4.03
$5.11
Volume194,645 shs
Average Volume1.60 million shs
Market Capitalization$140.38 million
P/E RatioN/A
Dividend YieldN/A
Beta2.2
Synlogic, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its therapeutic programs include SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with Ginkgo Bioworks for the development of synthetic biotic medicines. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
Synlogic logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SYBX
CUSIPN/A
Phone617-401-9975
Employees76
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.22 million
Book Value$4.86 per share

Profitability

Net Income$-51,370,000.00
Net Margins-2,761.83%

Miscellaneous

Market Cap$140.38 million
Next Earnings Date3/11/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.62 out of 5 stars

Medical Sector

292nd out of 1,958 stocks

Pharmaceutical Preparations Industry

145th out of 772 stocks

Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.3 5 -4 -3 -2 -1 -
$4.03
-0.01 (-0.25 %)
(As of 02/24/2021 04:30 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SYBX News and Ratings via Email

Sign-up to receive the latest news and ratings for SYBX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Synlogic (NASDAQ:SYBX) Frequently Asked Questions

Is Synlogic a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synlogic in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Synlogic stock.
View analyst ratings for Synlogic
or view top-rated stocks.

What stocks does MarketBeat like better than Synlogic?

Wall Street analysts have given Synlogic a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Synlogic wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Synlogic?

Synlogic saw a drop in short interest in January. As of January 29th, there was short interest totaling 334,500 shares, a drop of 74.1% from the January 14th total of 1,290,000 shares. Based on an average daily volume of 1,880,000 shares, the short-interest ratio is currently 0.2 days. Currently, 1.6% of the shares of the stock are sold short.
View Synlogic's Short Interest
.

When is Synlogic's next earnings date?

Synlogic is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Synlogic
.

How were Synlogic's earnings last quarter?

Synlogic, Inc. (NASDAQ:SYBX) issued its earnings results on Thursday, November, 5th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.47) by $0.11. Synlogic had a negative net margin of 2,761.83% and a negative trailing twelve-month return on equity of 41.64%.
View Synlogic's earnings history
.

How has Synlogic's stock price been impacted by Coronavirus?

Synlogic's stock was trading at $1.54 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, SYBX stock has increased by 161.7% and is now trading at $4.03.
View which stocks have been most impacted by COVID-19
.

When did Synlogic's stock split? How did Synlogic's stock split work?

Synlogic's stock reverse split on the morning of Monday, August 28th 2017. The 1-7 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 25th 2017. An investor that had 100 shares of Synlogic stock prior to the reverse split would have 14 shares after the split.

What price target have analysts set for SYBX?

3 equities research analysts have issued 12 month price objectives for Synlogic's stock. Their forecasts range from $10.00 to $13.00. On average, they expect Synlogic's stock price to reach $11.50 in the next year. This suggests a possible upside of 185.4% from the stock's current price.
View analysts' price targets for Synlogic
or view top-rated stocks among Wall Street analysts.

Who are Synlogic's key executives?

Synlogic's management team includes the following people:
  • Dr. Aoife M. Brennan M.D., MB, BCh, BAO, MMSc, Pres, CEO & Director (Age 45, Pay $737.3k)
  • Dr. Richard J. Riese M.D., Ph.D., Chief Medical Officer (Age 58, Pay $209.16k)
  • Prof. Timothy K. Lu, Co-Founder
  • Dr. James J. Collins, Co-Founder (Age 54)
  • Mr. Antoine Awad, Chief Operating Officer
  • Mr. Daniel Rosan, Head of Corp. Fin. & Investor Relations
  • Dr. David L. Hava, Chief Scientific Officer (Age 46)
  • Dr. Elizabeth Wolffe, Head of Investor Relations & Corp. Communications
  • Mr. Adam Thomas, Chief People Officer & Sec.
  • Dr. Caroline B. Kurtz Ph.D., Head of Translational Sciences & Product Devel.

Who are some of Synlogic's key competitors?

What other stocks do shareholders of Synlogic own?

What is Synlogic's stock symbol?

Synlogic trades on the NASDAQ under the ticker symbol "SYBX."

Who are Synlogic's major shareholders?

Synlogic's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (1.18%), Renaissance Technologies LLC (1.00%), Verition Fund Management LLC (0.07%), Jane Street Group LLC (0.05%), Flagship Harbor Advisors LLC (0.05%) and Monticello Wealth Management LLC (0.05%).
View institutional ownership trends for Synlogic
.

Which institutional investors are selling Synlogic stock?

SYBX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., and Jane Street Group LLC.
View insider buying and selling activity for Synlogic
or view top insider-selling stocks.

Which institutional investors are buying Synlogic stock?

SYBX stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Monticello Wealth Management LLC, Flagship Harbor Advisors LLC, and Verition Fund Management LLC.
View insider buying and selling activity for Synlogic
or or view top insider-buying stocks.

How do I buy shares of Synlogic?

Shares of SYBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Synlogic's stock price today?

One share of SYBX stock can currently be purchased for approximately $4.03.

How much money does Synlogic make?

Synlogic has a market capitalization of $140.38 million and generates $2.22 million in revenue each year. The biotechnology company earns $-51,370,000.00 in net income (profit) each year or ($1.70) on an earnings per share basis.

How many employees does Synlogic have?

Synlogic employs 76 workers across the globe.

What is Synlogic's official website?

The official website for Synlogic is www.synlogictx.com.

Where are Synlogic's headquarters?

Synlogic is headquartered at 301 Binney St. Suite 402, Cambridge MA, 02142.

How can I contact Synlogic?

Synlogic's mailing address is 301 Binney St. Suite 402, Cambridge MA, 02142. The biotechnology company can be reached via phone at 617-401-9975 or via email at [email protected]


This page was last updated on 2/24/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.